Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model

Open Access

Peer-reviewed

Research Article

Laura Ochoa-Callejero,

Affiliation Oncology Area, Center for Biomedical Research of La Rioja (CIBIR), Logroño, Spain
⨯
Laura Pérez-Martínez,

Affiliation Infectious Diseases Area, Center for Biomedical Research of La Rioja (CIBIR), Logroño, Spain
⨯
Susana Rubio-Mediavilla,

Affiliation Pathology Service, Hospital San Pedro, Logroño, Spain
⨯
José A. Oteo,

Affiliation Infectious Diseases Area, Center for Biomedical Research of La Rioja (CIBIR), Logroño, Spain
⨯
Alfredo Martínez ,

* E-mail: amartinezr@riojasalud.es

Affiliation Oncology Area, Center for Biomedical Research of La Rioja (CIBIR), Logroño, Spain
⨯
José R. Blanco

Affiliation Infectious Diseases Area, Center for Biomedical Research of La Rioja (CIBIR), Logroño, Spain
⨯

Reader Comments (2)

Diet
Is the Subject Area "Diet" applicable to this article?

Thanks for your feedback.
Hepatocellular carcinoma
Is the Subject Area "Hepatocellular carcinoma" applicable to this article?

Thanks for your feedback.
Fibrosis
Is the Subject Area "Fibrosis" applicable to this article?

Thanks for your feedback.
Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Chemokines
Is the Subject Area "Chemokines" applicable to this article?

Thanks for your feedback.
Liver fibrosis
Is the Subject Area "Liver fibrosis" applicable to this article?

Thanks for your feedback.
Mouse models
Is the Subject Area "Mouse models" applicable to this article?

Thanks for your feedback.